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cross-sectional survey was conducted among total of 350 diabetic patients randomly 
selected including 175 each from private and public hospitals. The study was con-
ducted from May to July 2012 including patients of having at least a year of illness 
and of 30 to 65 years of age. Results: The mean total cost per visit by a diabetic 
patient to a private hospital was US $14.3 (95% CI: 12.70 -16.92) as compared to US $ 
10.31(95% CI: 9.88- 12.36) for public hospital. Similarly, total direct cost for the treat-
ment and care of patients per month was US$ 58.10 (95% CI: 41.33-62.12) in private 
hospital in comparison to US $ 33.22 (95% CI: 27.32- 36.88) for those attending public 
hospitals. The per capita is just US$ 742. ConClusions: The study concludes that 
there was high economic burden on the patients with diabetes getting care from 
private sector as compared to public hospitals.
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objeCtives: Diabetes Mellitus (DM) is a chronic-degerenative disease in the popula-
tion connected to a high risk of onset of chronic complications and co-morbidities. 
Despite that, very low data are available on the cost associated. The objective of 
this study is to identify the available information about the epidemiology of the 
disease and to estimate the average annual cost incurred by the National Health 
Service (NHS) and by the Society for the treatment of diabetes in Italy. Methods: A 
probabilistic prevalence cost of Illness model was developed in order to calculate an 
aggregate measure of the economic burden associated with the disease in terms of 
direct medical (drug, hospitalization, monitoring and AE) and indirect costs (absen-
teeism and early retirement) . A systematic review of the literature was conducted 
to determine both the epidemiological and economic data. Furthermore, a one-way 
and probabilistic sensitivity analysis with 5,000 Monte Carlo simulations were per-
formed in order to test the robustness of the results and define a CI 95%. Results: 
The model estimated a prevalence of 2.6 million of patients with drug therapies 
in Italy. The total economic burden of diabetic patients in Italy amounted to € 20.3 
billion years (95% IC: € 18.61 - € 22.29 billion). Of these, 54% are associated with 
indirect costs (95% CI € 10.10 - € 11.62 billion) and 46% are attributable only to the 
direct costs (95% IC: € 8.11 - € 11 06 billion). ConClusions: This is a first study in 
Italy that aimed to estimate direct and indirect cost of diabetes with probabilistic 
prevalence approach. As might be expected, the lack of information means that the 
real burden of Diabetes is partly underestimated, especially about indirect costs. 
However, this approach can be very useful for policy makers in order to understand 
the economic aspects in the treatment of diabetes in Italy.
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objeCtives: Painful diabetic peripheral neuropathy (pDPN) results from toxic 
effects of chronically high blood sugar on the peripheral nervous system. Symptoms 
include loss of sensation, discomfort and often severe pain in the feet, legs or hands. 
The study aims to determine and characterize the potential total direct and indirect 
costs associated with pDPN in China. Methods: We created a one year model to 
estimate the burden of illness of pDPN in China. The model utilized a micro-costing 
approach. Direct health care costs were for primary treatment drugs, drugs for 
comorbidities, hospitalization utilization, tests, and outpatient visits. Indirect costs 
were projected due to both presenteeism (decreased productivity) and absenteeism 
(missing work). Prevalence rates and resource utilization frequency was informed by 
both publically available data and a questionnaire administered to local physicians. 
Both direct and indirect costs were informed by publically available data. Costs 
were reported in 2013 USD (1 USD = 6.07 RMB). Results: We estimated that pDPN 
affects 30% of the diabetic population—an estimated 33,930,810 people in China. 
The total economic burden of illness of pDPN was estimated to be $110.5 billion 
per year ($60.8 billion and $49.7 billion from direct and indirect costs, respectively). 
Within direct health care costs were primary treatment drugs ($37.1 billion), drugs 
for comorbidities ($13.9 billion), tests ($7.3 billion), hospitalizations ($1.7 billion), 
and outpatient visits ($713 million). For indirect costs, $42.6 billion was associated 
with presenteeism via decreased productivity, and $7.1 billion was associated with 
absenteeism. The estimated total cost per year, per patient is estimated to be $3,255 
($1,791 and $1,465 from direct and indirect costs respectively). ConClusions: In 
China, the aggregate burden of illness for pDPN is estimated to be over $110.5 bil-
lion annually. New treatments for the disease may reduce its burden on society.
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objeCtives: In diabetes management, self-monitoring of blood glucose (SMBG) and 
self-injection of insulin are necessary interventions to control blood glucose. However 
Chinese patients with type 2 diabetes (T2DM) have to pay almost all expenses for 
SMBG and self-injection from out-of-pocket. This paper is intended to calculate the 
costs of SMBG and self-injection for patients with T2DM in China. Methods: A cross-
sectional survey of patients with T2DM was carried out in one tertiary hospital in 
Tianjin and two community hopsitals in Beijing from October to December, 2011, 
which provided sufficient data for research question of this study. Costs of SMGB 
include glucometers and test strips; while costs of self-injection cover insulin pen 
objeCtives: Diabetes imposes a substantial health and economic burden to patients 
and society. This study analyzed the lifetime health care expenditures and life years 
lost associated with diabetes in the United States. Methods: Data from the National 
Health Interview Survey (NHIS), the NHIS linked Mortality Public-use Files, and the 
Medical Expenditure Panel Survey from 1997 to 2000 were used to estimate age-, race-, 
sex-, and body mass index (BMI)-specific risk of diabetes, mortality, and annual health 
care expenditures for both diabetics and non-diabetics. A Markov model populated by 
the risk estimates was used to compute life expectancy and total lifetime health care 
expenditures by age, race, sex, and BMI for diabetics and non-diabetics. Results: 
Predicted life expectancy was longer for females than males and whites and other 
races than blacks. Predicted life expectancy for diabetics and non-diabetics consist-
ently demonstrated an inverted U-shape for BMI across all subgroups, with highest life 
expectancy being for the overweight. Using U.S. adults aged 50 years as an example, 
we found that the life years lost associated with diabetes for white females with a BMI 
above 40 kg/m2 was 12.3 years. Black females of the same age and degree of obesity 
lost 11.2 life years, followed by white males (7.0 years) and black males (5.4 years). 
Lifetime health care expenditures between individuals with and without diabetes 
with a BMI above 40 kg/m42 varied by race and gender: white females ($48,848), black 
females ($47,787), white males ($31,189), and black males ($26,634). ConClusions: 
Our results show that obesity is associated with large decreases in life expectancy and 
large increases in lifetime health care expenditures. In addition, diabetes decreased 
life expectancy by 2.6 to 23.4 years and increased lifetime health care expenditures by 
$6,048 to $121,247 depending on age, gender, race, and BMI classification.
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objeCtives: Type 1 diabetes (T1D) and the associated comorbidities and complica-
tions create a financial burden for patients, caregivers, and the health care system. 
Understanding drivers of costs among specific patient sub-groups is important for 
targeting support initiatives. Methods: Data from a large Medicare Advantage 
payer were used. Members diagnosed with T1D and 24 months of continuous 
enrollment were included. Baseline demographic, clinical, consumer/behavioral, 
and cost characteristics were analyzed. Quantile regression (QR) was used to model 
the relationship between baseline characteristics and health care costs during the 
follow-up period (12 months) across cost quantiles. QR results were compared to 
traditional ordinary least squares (OLS) regression. Results: The sample included 
877 patients with T1D (mean age 65.2 yrs; 52% female). Common comorbidities 
included cardiovascular disease (46%), nephropathy (43%), and retinopathy (40%). QR 
analysis identified many interesting findings. For example, female gender is asso-
ciated with varying impact on costs across the continuum: lower impact in lower 
quantiles (-$24.61 in the 10th percentile, p< 0.10) but considerably higher impact in 
the top quantiles (-$5,537 in the 95th percentile, p< 0.10); however, no significant 
difference in costs was observed between genders in the OLS model. The presence 
of cardiovascular disease did not have a significant impact on costs in the OLS 
model, but showed a significant increase in costs in the lower quantiles ($429.08 in 
the 10th percentile) and a significant reduction in costs in the higher cost quantiles 
(-$4,737 and -$8,247; 90th and 95th percentiles, respectively). ConClusions: This 
study demonstrates the challenges in analyzing cost data due to variations in fac-
tors impacting health care costs across the cost continuum. Care should be taken 
when developing interventions directing resources at those most likely to benefit, 
as traditional regression analysis may be less useful than methods such as QR that 
provide more robust insights into patient sub-groups based on health care cost.
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objeCtives: The primary objective was to estimate the national burden of illness 
in Canada for diabetic foot ulcer (DFU) for 2011. Secondary objectives included 
estimating the national incidence and prevalence of DFU, and the 3-year aver-
age cost for DFU incident cases. Methods: Analyses were conducted using four 
national databases for the period April 1, 2006 to March 31, 2011, with cases being 
identified by ICD-10 CA codes. Resource utilization and costs, expressed in 2011 
Canadian dollars, were estimated for DFU-related hospitalizations, emergency care 
(ER), same day surgeries, home care, long term care, physician visits and caregiver 
time losses. Results: In Canada in the year 2011, DFU was attributed to 20,149 
hospital admissions (408,585 days), 32,174 ER or clinic visits, 110,924 rehabilitation 
clinic visits, and 26,493 interventions, including 6,036 amputations and 5,796 sur-
gical debridements. This acute institution care represented $455.0M, and with an 
additional $125.4M for home care and $63.1M for long term care, the annual cost 
for DFU-related care was $643.5M, or $25,141 annual cost per prevalent case. In 
2011, the national prevalence of DFU was 25,597 cases (75.1 per 100,000 population), 
consisting of 16,161 men (63.1%) and 9,436 women (36.9%), and an estimated 14,449 
incident cases. For an incident case of DFU, the average 3-year cumulative cost was 
$52,360. ConClusions: The annual burden for DFU cases that have at least one 
admission or ER/clinic visit over a 5-year period is higher than previously reported 
because of wound and vascular related admissions and procedures.
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objeCtives: The objective of the study was to estimate the direct and indirect cost 
of treatment among patients attending private and public hospitals. Methods: A 
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objeCtives: Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor 
approved for the treatment of adults with type 2 diabetes (T2DM). This study com-
pared the cost-effectiveness of dapagliflozin versus a sulfonylurea (SU) added to 
metformin in persons with T2DM inadequately controlled on metformin alone in 
Colombia. Methods: A discrete event simulation model (Cardiff diabetes model) 
based on UKPDS 68 was used to simulate disease progression and to estimate the 
economic and health treatment consequences in people with T2DM. Epidemiologic 
and clinical efficacy parameters were obtained from the literature. The cost of medi-
cation was obtained from country level price data, SISMED and Farmaprecios; the 
cost of macro- and microvascular events was based on POS tariffs, SOAT Manual 
and consultation with a local expert. Costs were expressed in US dollars [Exchange 
rate: 1,790.6 Colombian pesos = 1$]. A 20-year time horizon was assumed. Costs and 
health outcomes were discounted at 3% annually. Deterministic and probabilistic 
sensitivity analyses (PAS) were performed. Results: The total direct cost of the 
dapagliflozin + MET group over 20 years was higher than that of the SU added to 
metformin group ($11,482,424 vs. $8,942,315). Treatment with dapagliflozin resulted 
in a greater number of quality-adjusted life years (QALYs) compared to SU com-
bination (10,861 vs. 10,439).The calculated Incremental Cost-Effectiveness Ratio 
(ICER) for dapagliflozin compared to SU was $ 6,023 per QALY gained. Using WHO’s 
criteria, dapagliflozin compared to SU treatment strategy has a 85% probability of 
being highly cost-effective (ICER< 1 GDP per capita) and 100% probability of being 
cost-effective (ICER ≤ 3 GDP per capita).The results were robust to sensitivity analy-
sis. ConClusions: This study demonstrated that dapagliflozin in combination 
with metformin would be a cost-effective treatment option for patients who are 
inadequately controlled with metformin monotherapy in Colombia.
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objeCtives: To evaluate the long-term cost effectiveness of once daily biphasic 
insulin aspart 30 (BIAsp 30) versus insulin glargine (IGlarg) treating people with 
type 2 diabetes mellitus (T2DM) based on social perspective in China. Methods: 
The validated and peer-reviewed CORE Diabetes Model was employed to simulate 
disease progression and determine the total direct medical cost, life years (LYs) and 
quality-adjusted life years (QALYs) over 30 years. Simulated cohorts and treatment 
effects were based on the Chinese subgroup (n= 422) in the EasyMix study (identifier 
in ClinicalTrials.gov: NCT01123980) which was an open-label, randomized, two-arm 
and multicentre trial among insulin-naïve people with T2DM. Treatment costs were 
based on insulin doses in the trial and market retail prices in China. Management 
and complication costs were obtained from Chinese published data in 2011 and 
adjusted to the price level of 2012 with consumer price index. An annual discount-
ing rate of 3% was used for both costs and health outcomes. One-way sensitivity 
analyses were performed. Results: Treatment with BIAsp 30 was associated with 
LY gain of 0.09 (13.66 vs. 13.57) and QALY gain of 0.08 (9.72 vs. 9.64) compared with 
IGlarg over 30 years. In terms of total average cost per patient, BIAsp 30 was less 
costly than IGlarg (CNY -46,441, CNY 265,166 vs. 311,607) which was mainly induced 
by lower treatment and management cost (CNY-43,037, CNY 160,863 vs. 203,900) 
and complication cost (CNY -3404, CNY 104,303 vs. 107,707). Sensitivity analyses 
demonstrated robustness of the results. ConClusions: For people with T2DM 
insufficiently controlled on OADs in China, treatment with once daily BIAsp 30 
was projected to be associated with improved life expectancy and reduced direct 
medical cost compared to IGlarg. BIAsp 30 represented a dominant treatment option 
compared to IGlarg for people with T2DM failing to achieve adequate control with 
OADs in China.
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objeCtives: Long-term safety trials for new antidiabetic therapies are beginning 
to provide an alternative data source to inform the burden of patients with high 
cardiovascular (CV) risk who are of concern to payers, but are often excluded from 
efficacy trials. An economic model was used to anticipate the availability of CV 
safety outcome data from ongoing trials and assess the clinical, economic and 
quality of life impacts in patients with different high risk profiles. Methods: A 
discrete event simulation model was developed to capture 6 types of macrovas-
cular events and 2 key treatment events among patients with diabetes at high 
CV risk due to coronary heart disease (CHD), stroke and/or peripheral artery dis-
ease (PAD). Risk of clinical events depended on demographics and event history 
per UKPDS equations. Costs and utility values were based on published literature. 
Model outputs included event rates, CV-related costs and quality-adjusted life-years 
(QALYs). Results: Over a lifetime, in an example population with mean age of 
60 years, mean HbA1C of 8.5%, 70% CHD history, 30% stroke history and 30% PAD 
history, the CV event rate was 25.1/100-patient-years and annual per-patient cost 
was $12,776. This translated into 10.5 QALYs overall, ranging from 9.3 (patients with 
stroke history) to 11.2 (patients with CHD only) QALYs. A new intervention that 
reduces all CV event risks by 20%, results in 12.2 QALYs and annual cost of $10,611 
for the overall population. These burdens vary by up to 14% for plausible values of 
event risk after multiple events, with the burden among patients with stroke his-
tory being most sensitive. ConClusions: The clinical burden of CV events and the 
associated cost of care for patients with diabetes vary with baseline patient history 
and are subject to significant uncertainty. CV safety trials may provide clinical data 
to better quantify those burdens.
and needle. Results: 1) 614 patients with T2DM were surveyed and 71.45% used 
SMBG. For SMBG users, annual costs of glucometers were CNY 212.99; annual costs 
of test strips were CNY 825.55, estimated by multiplying average price (CNY 4.41) and 
frequency (3.60 per week); in total, SMBG cost CNY 1038.54 per person per year; 2) 
For insulin users, annual cost of insulin pens were CNY 396.34, estimated by average 
price (CNY 281.09) and frequency (1.41 per year); annual costs of needles were CNY 
634.20, estimated by average price (CNY 3.1) and frequency (204.58 per year, average 
reuse= 17.05 times); in total, self-injection cost CNY 1030.54 per person per year; 3) 
49.35% of surveyed patients used both insulin and SMBG. For this subgroup, annual 
costs of glucometers were CNY 199.05; annual costs of test strips were CNY 941.99, 
estimated by average price (CNY 4.41) and frequency (4.08 per week); In total was 
CNY 1141.04 per person per year. ConClusions: SMBG and self-injection caused 
considerable economic burdens to patients with T2DM in major cities in China, and 
more attention should be given to their out-of-pocket payment incurred by self-used 
devices and supplies.
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objeCtives: To investigate the frequency and cost of insulin pen needles reuse, 
and explore the factors that associated with needles reuse for insulin-treated dia-
betes patients in China. Methods: A questionnaire-based survey was conducted 
in 7 medical centres across China from June to September of 2012. Type 1 and type 
2 diabetes patients treated with insulin were included in the study. The data were 
analysed by descriptive analysis, Spearman correlation analysis, K-W and M-W 
U test using SPSS 19.0. Results: 592 eligible respondents (30 type 1 and 562 type 
2 diabetes patients) were included. One single needle was used 10.57 times base 
on 5% trimmed mean (8 times in median). 89.2% of patients reuse needles and 
60.5% reuse > 6 times. Among type 1 and type 2 diabetes, needles use frequencies 
base on 5% trimmed mean were 7.19 times (6 times in median) and 10.76 times 
(9 times in median), reuse of needles were 86.7% and 89.4%, needles reuse> 6 
times were 36.7% and 61.7%, respectively. Annual cost of needles was 237.0 CNY, 
estimated by the needle price of 2013 (NovoFine 32GTip, Novo Nordisk). The cost 
would be 2504.9 CNY/year if needles were used 1 time only. Economics burden was 
the most important factor of needles reuse for 68.9% of patients. Needles reuse 
was statistically and positively associated with age, diabetes duration, number of 
complications, value of fasting blood glucose, insulin injections times and dose, 
and was negative associated with income, with P-value< 0.05. ConClusions: 
Needles reuse for insulin injection was a common phenomenon in insulin-treated 
diabetes patients in China. Economic burden was the main reason of needles 
reuse. Other influencing factors of needles reuse included age, diabetes-related 
health status and insulin use.
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objeCtives: To describe the prevalence, frequency and cost of SMBG, and explore the 
factors that influence SMBG for insulin-treated diabetes patients in China. Methods: 
A questionnaire-based survey was conducted in 7 medical centres across China from 
June to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included in the study. The data were analysed by descriptive analysis, Spearman 
correlation analysis, K-W and M-W U test using SPSS 19.0. Results: 602 eligible 
respondents (4.98% type 1 and 95.02% type 2 diabetes patients) were included. 85.0% 
of patients practiced SMBG with the frequency of 0.61±0.94 times/day. Among type 1 
and type 2 diabetes patients, the prevalence and frequency of SMBG were 90.0% and 
1.05 times/day, 84.8% and 0.59 times/day, respectively. Taking global recommended 
SMBG frequency into account, only 18.76% of type 2 diabetes patients conducted 
SMBG ≥ 1 time/day, and 7.4% of type 1 diabetes patients conducted SMBG ≥ 3 times/
day. Annual cost of SMBG was 1170 CNY, estimated by the market price of 5 CNY/
test trip. 20.5% of patients thought the cost of test trips was the most important 
factor to SMBG use. SMBG frequency was statistically and positively correlated with 
frequency and doses of insulin daily use, frequency and related cost of hypoglycae-
mia, drug cost, frequency and cost of hospitalization and clinical visit, with P-value 
< 0.05. ConClusions: SMBG was not conducted enough in insulin-treated diabetes 
patients in China. Economic burden of test trips was one of the main barriers to 
SMBG use. Factors influencing SMBG included insulin use, hypoglycaemia, drug costs, 
frequency and cost of hospitalization and clinic visit.
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